Study on the Influence of Nutritional Indices on the Prognosis of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

With the decline of virulence after the mutation of the SARS-CoV-2 , based on the national life and health and national development needs, the domestic SARS-CoV-2 infection epidemic prevention policy has changed, and the number of people infected by the SARS-CoV-2 has increased. Nutritional status is an indicator of human health and plays an important role in fighting disease. Malnutrition has been found to correlate with prognosis in patients infected with the SARS-CoV-2 infection . Timely identification and assessment of the patient's nutritional status and early implementation of relevant nutritional intervention are conducive to the recovery of the patient's condition. In clinical practice, it is necessary to improve nutrition as an aspect of the comprehensive diagnosis and treatment of patients with SARS-CoV-2 infection, but there is still a lack of relevant nutritional indicators or models to simply and accurately assess the nutritional status of patients.The purpose of this study was to evaluate the effects of PNI, NRI, GNRI, albumin level, vitamin D, chest muscle area and density on the clinical characteristics and prognosis of patients with SARS-CoV-2 infection, to find the nutritional predictors of severe disease in patients with SARS-CoV-2 infection, and to establish a simpler and more accurate nutritional evaluation model. To provide evidence for targeted nutritional interventions in patients with SARS-CoV-2 infection.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Patients with a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 antigen test.

Locations
Other Locations
China
The Second Affiliated Hospital of Chongqing Medical University
RECRUITING
Chongqing
Contact Information
Primary
Juan Kang, M.D.
68368892@qq.com
8613996112052
Time Frame
Start Date: 2023-05-01
Estimated Completion Date: 2025-12-09
Participants
Target number of participants: 800
Treatments
Patients With SARS-CoV-2 Infection
Patients who test positive for SARS-CoV-2 nucleic acid or SARS-CoV-2 antigen
Sponsors
Leads: Juan Kang

This content was sourced from clinicaltrials.gov